Center-Authored Papers

Filters: Author is Shustov, Andrei R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Adams SV, Newcomb PA, Shustov AR.  2016.  Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B et al..  2016.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.. British journal of haematology. 172(4):535-544. Abstract
B
Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS et al..  2016.  Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.. Leukemia & lymphoma. :1-10. Abstract
Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer BE, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR et al..  2011.  Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.. British journal of haematology. 155(2):182-9. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE et al..  2013.  A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.. British journal of haematology. 161(2):183-91. Abstract
C
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI et al..  2015.  High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97. Abstract
Cassaday RD, Alan Potts D, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC et al..  2016.  Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.. Leukemia & lymphoma. :1-10. Abstract
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD et al..  2015.  Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
F
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D et al..  2014.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(28):3137-43. Abstract
Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK.  2012.  Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms.. Clinical lymphoma, myeloma & leukemia.
G
Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE et al..  2010.  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.. Leukemia & lymphoma. 51(8):1523-9. Abstract
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J et al..  2013.  Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy.. Leukemia & lymphoma. Abstract
Gopal AK, Pro B, Connors JM, Younes A, Engert A, Shustov AR, Chi X, Larsen EK, Kennedy DA, Sievers EL.  2016.  Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.. Clinical trials (London, England). 13(5):545-54. Abstract
H
Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA et al..  2016.  A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.. Cancer. Abstract
Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA et al..  2017.  Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.. Clinical lymphoma, myeloma & leukemia. Abstract
I
Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A et al..  2014.  Allogeneic Transplant Following Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma.. Leukemia & lymphoma. :1-34. Abstract
O
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM et al..  2015.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.. Hematological oncology. 33(4):187-191. Abstract
P
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI et al..  2015.  Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6. Abstract
Pro B, Horwitz SM, Prince MH, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Padmanabhan Iyer S et al..  2016.  Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.. Hematological oncology.
R
Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O'Donnell PV, Sandmaier BM et al..  2011.  Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45. Abstract
S
Shadman M, Gopal AK, Kammerer B, Becker PS, Maloney DG, Pender B, Shustov AR, Press OW, Pagel JM.  2015.  Radioimmunotherapy Consolidation using (131)I-Tositumomab for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission.. Leukemia & lymphoma. 57(3):572-6. Abstract
Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R et al..  2010.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.. British journal of haematology. 150(2):170-8. Abstract